In-Use Test With a Cosmetic Product to Treat Pruritus

In-Use Test With a Cosmetic Product (WO 3308) for Topical Use to Treat Acute or Chronic Pruritus

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03477058

Enrollment

Registered

2018-03-26

Start date

2017-01-23

Completion date

2017-02-06

Last updated

2023-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pruritus

Keywords

chronic pruritus, acute pruritus

Brief summary

The aim of the study is to evaluate the cosmetic features of the product WO 3308 by means of a questionnaire in an interview situation after two weeks of product treatment, giving special consideration to the cosmetic performance, efficacy and skin compatibility and with special focus on the reduction of pruritus. Additionally the tolerance will be evaluated by a dermatologist.

Interventions

OTHERWO 3308 cosmetic product for topical use

Application on the entire body at least once a day over two weeks

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 99 Years

Healthy volunteers

Inclusion criteria

* age: ≥ 18 years * sex: approx. 25% to 50% male and 50% to 75% female * with acute pruritus (lasts less than 6 weeks) or chronic pruritus (lasts longer than 6 weeks): max. 50% with acute pruritus and at least 50% with chronic pruritus

Exclusion criteria

* any deviation from the above-mentioned criteria * known incompatibilities to cosmetics and ingredients of cosmetic test products (please see INCI) * topical medication in the test area within 1 month prior to study start * systemic medication with antibiotics within 2 weeks prior to starting of the study * change in the medication with anti-inflammatory agents within 2 weeks prior to starting the study * systemic medication with immunomodulators (immunsuppressive drugs in the course of a transplantation) and/or chemotherapeutic agents within 4 weeks prior to starting the study * neurodermatitis (atopic dermatitis) * pregnancy and period of breastfeeding

Design outcomes

Primary

Measure	Time frame	Description
Cosmetic Features of the Test Product	baseline, two weeks	Change from baseline for the cosmetic features (spreadability, absorbtion, skin feeling after application, fragrance) of the test product by the means of an interview-based questionnaire
Reduction of Pruritus	baseline, two weeks	Change from baseline reduction of pruritus at two weeks by the means of an interview-based questionnaire

Secondary

Measure	Time frame	Description
Tolerance of the Test Product on the skin	baseline, two weeks	Change from baseline at two weeks by the means of a dermatological and subjective assessment of skin tolerance on arms and legs

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026